Listing 1 - 6 of 6 |
Sort by
|
Choose an application
Stem cells. --- Stem cells --- Transplantation. --- Stem cell transplantation --- Cell transplantation --- Colony-forming units (Cells) --- Mother cells --- Progenitor cells --- Cells
Choose an application
Cèl·lules mare --- Cèl·lules --- Cèl·lules mare embrionàries --- Stem cells. --- Stem cells --- Regenerative medicine. --- Transplantation. --- Medicine --- Regeneration (Biology) --- Stem cell transplantation --- Cell transplantation --- Colony-forming units (Cells) --- Mother cells --- Progenitor cells --- Cells
Choose an application
This open access book provides a concise yet comprehensive overview on how to build a quality management program for hematopoietic stem cell transplantation (HSCT) and cellular therapy. The text reviews all the essential steps and elements necessary for establishing a quality management program and achieving accreditation in HSCT and cellular therapy. Specific areas of focus include document development and implementation, audits and validation, performance measurement, writing a quality management plan, the accreditation process, data management, and maintaining a quality management program. Written by experts in the field, Quality Management and Accreditation in Hematopoietic Stem Cell Transplantation and Cellular Therapy: A Practical Guide is a valuable resource for physicians, healthcare professionals, and laboratory staff involved in the creation and maintenance of a state-of-the-art HSCT and cellular therapy program.
Haematology --- Oncology --- Hematology --- Blood Transfusion Medicine --- Internal Medicine --- outcome analysis --- structural indicators --- process indicators --- Hematopoietic Stem Cell Transplantation --- Quality Management --- Audits --- Qualification and Validation --- Personnel Requirements --- Performance Measurement --- Tracking and Traceability --- Adverse Events --- Quality Management Plan --- Accreditation --- Data Management --- Training --- Risk Management --- JACIE
Choose an application
This updated and expanded edition developed by the Blood and Marrow Stem Cell Transplant team at Oregon Health & Science University Knight Cancer Institute features the latest medical management guidelines and standards of care for hematopoietic stem cell transplant and cellular therapy patients. Spanning the timeline from the initial consultation throughout the transplant process, this handbook begins by providing a general overview of stem cell transplantation and goes on to outline disease-specific indications for stem cell transplantation. It then focuses on transplant complications and ongoing care, and finally explores cellular therapies for hematologic malignancies. Comprehensive and easy-to-use, Blood and Marrow Transplant Handbook: Comprehensive Guide for Patient Care, Third Edition presents a multidisciplinary approach to information for physicians and advanced practice medical providers as well as residents, fellows, and other trainees who care for patients who undergo transplant and immune effector cell therapy.
Surgical transplantation. --- Hematology. --- Oncology . --- Transplant Surgery. --- Oncology. --- Tumors --- Haematology --- Internal medicine --- Blood --- Medical transplantation --- Organ transplantation --- Organ transplants --- Organs (Anatomy) --- Surgical transplantation --- Tissue transplantation --- Tissues --- Transplant surgery --- Transplantation surgery --- Transplants, Organ --- Surgery --- Preservation of organs, tissues, etc. --- Procurement of organs, tissues, etc. --- Diseases --- Transplantation --- Hematopoietic stem cells --- Hematopoietic Stem Cell Transplantation --- Nursing --- Nursing. --- HSCs (Hematopoietic stem cells) --- Blood cells --- Bone marrow cells --- Hematopoietic system --- Multipotent stem cells
Choose an application
The concept of advanced therapy medicinal products (ATMPs) encompasses novel kinds of medicines for human use that are based on genes, cells or tissues. These intend to offer not only regeneration, but complete functional recovery of diseased tissues and organs using different strategies. Gene therapy, cell therapy and tissue engineering are the main areas in which promising advanced therapies are emerging. The eye is a very complex organ whose main structures, the cornea and the retina, play a pivotal role in maintaining normal vision, as severe alterations in these tissues can lead to blindness. Ocular tissues are starting to benefit from ATMPs by fighting against the enormous complexity and devastating potential of many ocular diseases. However, developments arising from this field of work face important challenges related to vectors to deliver drugs and genetic material to target tissues, suitable biomaterials to prepare cell scaffolds and cell stemness, among others—not to mention the complicated legislation around ATMPs, the complexity in production and quality control and the absence of standardized protocols.The purpose of this Special Issue is to serve as an overview of the current progress in the application of cell and gene therapies, as well as tissue engineering to restore functionality in diseased ocular structures, and the challenges linked to reaching patients.
MPC polymer --- dry eye --- ocular surface --- lacrimal fluid --- mucin --- 3D bioprinting --- cornea --- retina --- ophthalmology --- tissue regeneration --- electrospinning --- conjunctiva --- decellularized tissue matrix --- small intestinal submucosa --- urinary bladder matrix --- polycaprolactone --- fiber --- tissue engineering --- stratification --- conjunctival epithelial cells --- hydrogel --- keratoplasty --- scaffold --- collagen --- advanced therapy medicinal product --- ATMP --- cell therapy --- gene therapy --- eye --- ocular --- regulatory --- marketing authorization --- double-crosslinking --- carbodiimide --- glutaraldehyde --- sodium metabisulfite --- sodium borohydride --- EDC/NHS --- stem cells --- retinal diseases --- optic nerve diseases --- cell replacement --- cell sources --- advanced therapies --- ocular mucosa --- blindness --- CLET --- limbal niche --- limbal stem cell --- LSCD --- mesenchymal stem cell transplantation --- MSCT --- corneal limbus --- decellularized xenograft --- recellularization --- mesenchymal stem cells --- n/a
Choose an application
The concept of advanced therapy medicinal products (ATMPs) encompasses novel kinds of medicines for human use that are based on genes, cells or tissues. These intend to offer not only regeneration, but complete functional recovery of diseased tissues and organs using different strategies. Gene therapy, cell therapy and tissue engineering are the main areas in which promising advanced therapies are emerging. The eye is a very complex organ whose main structures, the cornea and the retina, play a pivotal role in maintaining normal vision, as severe alterations in these tissues can lead to blindness. Ocular tissues are starting to benefit from ATMPs by fighting against the enormous complexity and devastating potential of many ocular diseases. However, developments arising from this field of work face important challenges related to vectors to deliver drugs and genetic material to target tissues, suitable biomaterials to prepare cell scaffolds and cell stemness, among others—not to mention the complicated legislation around ATMPs, the complexity in production and quality control and the absence of standardized protocols.The purpose of this Special Issue is to serve as an overview of the current progress in the application of cell and gene therapies, as well as tissue engineering to restore functionality in diseased ocular structures, and the challenges linked to reaching patients.
Medicine --- MPC polymer --- dry eye --- ocular surface --- lacrimal fluid --- mucin --- 3D bioprinting --- cornea --- retina --- ophthalmology --- tissue regeneration --- electrospinning --- conjunctiva --- decellularized tissue matrix --- small intestinal submucosa --- urinary bladder matrix --- polycaprolactone --- fiber --- tissue engineering --- stratification --- conjunctival epithelial cells --- hydrogel --- keratoplasty --- scaffold --- collagen --- advanced therapy medicinal product --- ATMP --- cell therapy --- gene therapy --- eye --- ocular --- regulatory --- marketing authorization --- double-crosslinking --- carbodiimide --- glutaraldehyde --- sodium metabisulfite --- sodium borohydride --- EDC/NHS --- stem cells --- retinal diseases --- optic nerve diseases --- cell replacement --- cell sources --- advanced therapies --- ocular mucosa --- blindness --- CLET --- limbal niche --- limbal stem cell --- LSCD --- mesenchymal stem cell transplantation --- MSCT --- corneal limbus --- decellularized xenograft --- recellularization --- mesenchymal stem cells --- MPC polymer --- dry eye --- ocular surface --- lacrimal fluid --- mucin --- 3D bioprinting --- cornea --- retina --- ophthalmology --- tissue regeneration --- electrospinning --- conjunctiva --- decellularized tissue matrix --- small intestinal submucosa --- urinary bladder matrix --- polycaprolactone --- fiber --- tissue engineering --- stratification --- conjunctival epithelial cells --- hydrogel --- keratoplasty --- scaffold --- collagen --- advanced therapy medicinal product --- ATMP --- cell therapy --- gene therapy --- eye --- ocular --- regulatory --- marketing authorization --- double-crosslinking --- carbodiimide --- glutaraldehyde --- sodium metabisulfite --- sodium borohydride --- EDC/NHS --- stem cells --- retinal diseases --- optic nerve diseases --- cell replacement --- cell sources --- advanced therapies --- ocular mucosa --- blindness --- CLET --- limbal niche --- limbal stem cell --- LSCD --- mesenchymal stem cell transplantation --- MSCT --- corneal limbus --- decellularized xenograft --- recellularization --- mesenchymal stem cells
Listing 1 - 6 of 6 |
Sort by
|